瑞戈非尼治疗晚期结直肠癌患者的长期生存：病例报告及文献综述
Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review.
作者信息
Brunetti Oronzo, Calabrese Angela, Palermo Loredana, Solimando Antonio Giovanni, Argentiero Antonella
机构信息
Medical Oncology Unit IRCCS Istituto Tumori "Giovanni Paolo II" Bari Italy.
Radiology Unit IRCCS Istituto Tumori "Giovanni Paolo II" Bari Italy.
出版信息
Clin Case Rep. 2019 Oct 24;7(12):2379-2383. doi: 10.1002/ccr3.2496. eCollection 2019 Dec.
Two phase 3 trials reported a prolonged survival in the third-line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable disease with regorafenib.
两项3期试验报告称，接受瑞戈非尼治疗的结直肠癌患者在三线治疗中生存期延长，最长治疗时间为16个月。在此，我们报告了一例对传统化疗难治的患者，该患者接受瑞戈非尼治疗后疾病长期稳定的独特病例。
Zotero 插件